Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation.

Journal of hematology & oncology - 4 Nov 2024

Dong Jing, Arsang-Jang Shahram, Zhang Tao, Chen Zhongyuan, Bolon Yung-Tsi, Spellman Stephen, Urrutia Raul, Auer Paul, Saber Wael

Abstract excerpt

Mitochondrial DNA (mtDNA) variants in patients with myelodysplastic neoplasms (MDS) are shown to be prognostic of outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). However, the prognostic impact of donor mtDNA variants is unknown. Here, we performed whole-genome sequencing on 494 donors who were matched to MDS patients enrolled in the Center for International Blood and Marrow Transplant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to DNA, Mitochondrial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Mitochondrial

Share to Hematopoietic Stem Cell Transplantation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Tissue Donors

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39497145
DOI: 10.1186/s13045-024-01622-w
PMCID: PMC11533675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation.PMID 39497145Read ↗

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.Semantic proximity Read ↗

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.Semantic proximity Read ↗

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR studySemantic proximity Read ↗

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.Semantic proximity Read ↗

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Improving Prognostic Modeling in Myelodysplastic Syndromes.Semantic proximity Read ↗

Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.Semantic proximity Read ↗

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.Semantic proximity Read ↗

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.